Citigroup’s NeuroSense Therapeutics NRSN Stock Holding History

Citigroup’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,487	Closed	-$168K	–	6174
2022 Q2	$168K	Buy	2,487 +2,486	+248,600%	+$94.2K	﹤0.01%	3944
2022 Q1	$0	Buy	+1	New	+$48	﹤0.01%	6521

Other funds holding NRSN

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Citigroup's NRSN Position: Q3 2022 in Review

Citigroup sold out of NeuroSense Therapeutics (NRSN) in Q3 2022, closing a stake of 2,487 shares — an estimated $168K sold.

Citigroup first reported a position in NRSN in Q1 2022 and held it in 2 quarters. The position peaked at $168K in Q2 2022. 4 funds tracked by Wall St. Rank hold NRSN as of Q3 2022.

Citigroup reported no remaining NeuroSense Therapeutics position as of Q3 2022 after selling out during the quarter.
Citigroup sold 2,487 NeuroSense Therapeutics shares in Q3 2022, an estimated $168K.
Citigroup first reported a position in NeuroSense Therapeutics in Q1 2022 and held it in 2 quarters.
Citigroup's NeuroSense Therapeutics position peaked at $168K in Q2 2022.
4 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.